Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Mackey, JR; Martin, M; Pienkowski, T; Rolski, J; Guastalla, JP; Sami, A; Glaspy, J; Juhos, E; Wardley, A; Fornander, T; Hainsworth, J; Coleman, R; Modiano, MR; Vinholes, J; Pinter, T; Rodriguez-Lescure, A; Colwell, B; Whitlock, P; Provencher, L; Laing, K; Walde, D; Price, C; Hugh, JC; Childs, BH; Bassi, K; Lindsay, MA; Wilson, V; Rupin, M; Houe, V; Vogel, C.

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial

LANCET ONCOLOGY. 2013; 14(1): 72-80 Nº de citas: 185 [doi:10.1016/S1470-2045(12)70525-9]

Khouri, MG; Douglas, PS; Mackey, JR; Martin, M; Scott, JM; Scherrer-Crosbie, M; Jones, LW.

Cancer Therapy-Induced Cardiac Toxicity in Early Breast Cancer Addressing the Unresolved Issues

CIRCULATION. 2012; 126(23): 2749-2763 Nº de citas: 195 [doi:10.1161/CIRCULATIONAHA.112.100560]

Vahdat, LT; Thomas, ES; Roche, HH; Hortobagyi, GN; Sparano, JA; Yelle, L; Fornier, MN; Martin, M; Bunnell, CA; Mukhopadhyay, P; Peck, RA; Perez, EA.

Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials

SUPPORTIVE CARE IN CANCER. 2012; 20(11): 2661-2668 Nº de citas: 30 [doi:10.1007/s00520-012-1384-0]

Bastien, RRL; Rodriguez-Lescure, A; Ebbert, MTW; Prat, A; Munarriz, B; Rowe, L; Miller, P; Ruiz-Borrego, M; Anderson, D; Lyons, B; Alvarez, I; Dowell, T; Wall, D; Segui, MA; Barley, L; Boucher, KM; Alba, E; Pappas, L; Davis, CA; Aranda, I; Fauron, C; Stijleman, IJ; Palacios, J; Anton, A; Carrasco, E; Caballero, R; Ellis, MJ; Nielsen, TO; Perou, CM; Astill, M; Bernard, PS; Martin, M.

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

BMC MEDICAL GENOMICS. 2012; 5: Nº de citas: 292 [doi:10.1186/1755-8794-5-44]

Serra-Rexach, JA; Jimenez, AB; Garcia-Alhambra, MA; Pla, R; Vidan, M; Rodriguez, P; Ortiz, J; Garcia-Alfonso, P; Martin, M.

Differences in the Therapeutic Approach to Colorectal Cancer in Young and Elderly Patients

ONCOLOGIST. 2012; 17(10): 1277-1285 Nº de citas: 61 [doi:10.1634/theoncologist.2012-0060]

Martin, M; Bell, R; Bourgeois, H; Brufsky, A; Diel, I; Eniu, A; Fallowfield, L; Fujiwara, Y; Jassem, J; Paterson, AHG; Ritchie, D; Steger, GG; Stopeck, A; Vogel, C; Fan, M; Jiang, Q; Chung, KR; Dansey, R; Braun, A.

Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid

CLINICAL CANCER RESEARCH. 2012; 18(17): 4841-4849 Nº de citas: 108 [doi:10.1158/1078-0432.CCR-11-3310]

Duenas, M; Santos, M; Aranda, JF; Bielza, C; Martinez-Cruz, AB; Lorz, C; Taron, M; Ciruelos, EM; Rodriguez-Peralto, JL; Martin, M; Larranaga, P; Dahabreh, J; Stathopoulos, GP; Rosell, R; Paramio, JM; Garcia-Escudero, R.

Mouse p53-Deficient Cancer Models as Platforms for Obtaining Genomic Predictors of Human Cancer Clinical Outcomes

PLoS One. 2012; 7(8): Nº de citas: 7 [doi:10.1371/journal.pone.0042494]

Jacquin, JP; Jones, S; Magne, N; Chapelle, C; Ellis, P; Janni, W; Mavroudis, D; Martin, M; Laporte, S.

Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials

BREAST CANCER RESEARCH AND TREATMENT. 2012; 134(3): 903-913 Nº de citas: 26 [doi:10.1007/s10549-011-1933-0]

von Minckwitz, G; Martin, M.

Neoadjuvant treatments for triple-negative breast cancer (TNBC)

ANNALS OF ONCOLOGY. 2012; 23: 35-39 Nº de citas: 107 [doi:10.1093/annonc/mds193]

Romero, A; Martin, M; Oliva, B; de la Torre, J; Furio, V; de la Hoya, M; Garcia-Saenz, JA; Moreno, A; Roman, JM; Diaz-Rubio, E; Caldes, T.

Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients

ANNALS OF ONCOLOGY. 2012; 23(7): 1750-1756 Nº de citas: 34 [doi:10.1093/annonc/mdr483]

Chen, AC; Migliaccio, I; Rimawi, M; Lopez-Tarruella, S; Creighton, CJ; Massarweh, S; Huang, C; Wang, YC; Batra, SK; Gutierrez, MC; Osborne, CK; Schiff, R.

Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies

BREAST CANCER RESEARCH AND TREATMENT. 2012; 134(2): 583-593 Nº de citas: 27 [doi:10.1007/s10549-012-2082-9]

Virizuela, JA; Escobar, Y; Cassinello, J; Borrega, P.

Treatment of cancer pain: Spanish Society of Medical Oncology (SEOM) recommendations for clinical practice

CLINICAL & TRANSLATIONAL ONCOLOGY. 2012; 14(7): 499-504 Nº de citas: 23 [doi:10.1007/s12094-012-0831-1]

Hurvitz, SA; Betting, DJ; Stem, HM; Quinaux, E; Stinson, J; Seshagiri, S; Zhao, Y; Buyse, M; Mackey, J; Driga, A; Damaraju, S; Sliwkowski, MX; Robert, NJ; Valero, V; Crown, J; Falkson, C; Brufsky, A; Pienkowski, T; Eiermann, W; Martin, M; Bee, V; Marathe, O; Slamon, DJ; Timmerman, JM.

Analysis of Fc gamma Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

CLINICAL CANCER RESEARCH. 2012; 18(12): 3478-3486 Nº de citas: 103 [doi:10.1158/1078-0432.CCR-11-2294]

Lopez-Tarruella, S; Jerez, Y; Marquez-Rodas, I; Martin, M.

Neratinib (HKI-272) in the treatment of breast cancer

Future Oncology. 2012; 8(6): 671-681 Nº de citas: 23 [doi:10.2217/FON.12.66]

Guisado-Vasco, P; Arranz-Saez, R; Canales, M; Canovas, A; Garcia-Larana, J; Garcia-Sanz, R; Lopez, A; Lopez, JL; Llanos, M; Moraleda, JM; Rodriguez, J; Rayon, C; Sabin, P; Salar, A; Marin-Niebla, A; Morente, M; Sanchez-Godoy, P; Tomas, JF; Muriel, A; Abraira, V; Piris, MA; Garcia, JF; Montalban, C.

Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series

LEUKEMIA & LYMPHOMA. 2012; 53(5): 812-819 Nº de citas: 15 [doi:10.3109/10428194.2011.635861]

Gutierrez, LC; Khosravi-Shahi, P; Alvarez, YE.

Management of dermatitis in patients with locally advanced squamous cell carcinoma of the head and neck receiving cetuximab and radiotherapy

ORAL ONCOLOGY. 2012; 48(4): 293-297 Nº de citas: 18 [doi:10.1016/j.oraloncology.2011.10.019]

Martin, M; Makhson, A; Gligorov, J; Lichinitser, M; Lluch, A; Semiglazov, V; Scotto, N; Mitchell, L; Tjulandin, S.

Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer

ONCOLOGIST. 2012; 17(4): 469-475 Nº de citas: 38 [doi:10.1634/theoncologist.2011-0344]

Miles, D; Zielinski, C; Martin, M; Vrdoljak, E; Robert, N.

Combining capecitabine and bevacizumab in metastatic breast cancer: A comprehensive review

EUROPEAN JOURNAL OF CANCER. 2012; 48(4): 482-491 Nº de citas: 16 [doi:10.1016/j.ejca.2011.12.007]